BRKR trades 16.7% above Wall Street's consensus target of $47.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BRKR achieves its forward estimates and maintains a stable P/E multiple of 27.0x. This scenario reflects the blended consensus of 32 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Bruker Corporation (BRKR) has a Wall Street consensus price target of $47.67, based on estimates from 32 covering analysts. With the stock currently trading at $57.23, this represents a potential downside of -16.7%. The company has a market capitalization of $8.71B.
Analyst price targets range from a low of $35.00 to a high of $58.00, representing a 48% spread in expectations. The median target of $47.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BRKR trades at a trailing P/E of -381.5x and forward P/E of 27.0x. Analysts expect EPS to grow +2888.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $25.46, with bear and bull scenarios of $16.04 and $33.55 respectively. Model confidence stands at 43/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
WATWaters Corporation | $23.2B | $355.44 | $395.25 | +11.2% | Hold | 24.5x | 35 |
TRMBTrimble Inc. | $11.6B | $49.16 | $90.50 | +84.1% | Buy | 15.9x | 28 |
FTVFortive Corporation | $18.8B | $61.03 | $62.00 | +1.6% | Hold | 20.4x | 30 |
AAgilent Technologies, Inc. | $35.9B | $127.06 | $154.75 | +21.8% | Buy | 21.0x | 41 |
TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
MTDMettler-Toledo International Inc. | $23.1B | $1144.84 | $1392.25 | +21.6% | Hold | 24.5x | 19 |
ROPRoper Technologies, Inc. | $34.0B | $330.25 | $457.64 | +38.6% | Buy | 15.1x | 23 |
DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
BIOBio-Rad Laboratories, Inc. | $7.6B | $282.44 | $321.67 | +13.9% | Buy | 31.2x | 14 |
Quick answers to the most common questions about buying BRKR stock.
BRKR's consensus price target is $47.67, -16.7% below the current price of $57.23. The 32 analysts tracking BRKR see downside risk at present valuations.
BRKR has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is mixed, with 14 Hold ratings making up the largest segment. The consensus 12-month price target of $47.67 implies -16.7% downside from current levels.
BRKR trades at a forward P/E of 27.0017x, representing a moderate valuation. With analysts targeting $47.67 (-16.7% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $58 for BRKR, while the most conservative target is $35. The consensus of $47.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $34 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BRKR is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 14 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BRKR stock forecast based on 32 Wall Street analysts shows a consensus price target of $47.67, with estimates ranging from $35 (bear case) to $58 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $25, with bear/bull scenarios of $16/$34.
Our quantitative valuation model calculates BRKR's fair value at $25 (base case), with a bear case of $16 and bull case of $34. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.
BRKR trades at a forward P/E ratio of 27.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on BRKR, with 2 Sell ratings and a price target of $47.67 (-16.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BRKR analyst price targets range from $35 to $58, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $47.67 consensus represents the middle ground. Our model's $16-$34 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.